Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: onr:"swepub:oai:gup.ub.gu.se/321610" > Long-term Outcomes ...

1 av 1
Föregående post
Nästa post
Till träfflistan

Ventimiglia, EugenioUppsala universitet,Urologkirurgi,IRCCS Osped San Raffaele, Div Expt Oncol, Urol Res Inst, Unit Urol, Milan, Italy. (författare)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden.

Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

2022-09-14
American Medical Association (AMA),2022

Nummerbeteckningar

LIBRIS-ID:oai:gup.ub.gu.se/321610
https://gup.ub.gu.se/publication/321610URI
https://doi.org/10.1001/jamanetworkopen.2022.31015DOI
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485959URI

Kompletterande språkuppgifter

Språk:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

The long-term outcomes among men with prostate cancer (PC) whose disease is managed with active surveillance (AS) remains unknown.To develop a simulation model with a 30-year follow-up for men with PC managed with AS.In this cohort study, a state transition model was created using data from Prostate Cancer data Base Sweden (PCBaSe) on 23655 men diagnosed with PC and managed with deferred treatment to estimate treatment trajectories. A simulation was performed with 100000 men in each combination of age at diagnosis, Charlson Comorbidity Index, and PC risk with a follow-up of 30 years.Death from PC and death from other causes were estimated, and the proportion of time without active PC treatment was assessed until date of death or age 85 years.This study included 23655 men from PCBaSe with a median age at diagnosis of 69 years (IQR, 64-74 years). Of these, 16177 men underwent active surveillance for PC and 7478 underwent watchful waiting. The proportion of men who were diagnosed at age 55 years and died of PC before age 85 years was 9% for very low-risk PC, 13% for low-risk PC, and 15% for intermediate-risk PC. Among men with a Charlson Comorbidity Index of 0 who were diagnosed at age 70 years, the corresponding percentages were 3%, 6%, and 7%, respectively. The mean proportion of remaining life-years without active PC treatment for men diagnosed at age 55 years was 12 of 25 years (48%) for very low-risk PC, 9 of 25 years (36%) for low-risk PC, and 7 of 25 (29%) for intermediate-risk PC. For men aged 70 years, the corresponding numbers were 10 of 13 years (77%), 9 of 13 years (66%), and 8 of 13 years (60%), respectively. Men with intermediate-risk PC who were younger than 60 years at diagnosis had a high risk of PC death (12%-15%) and fewer remaining life-years without active PC treatment (29%-33%). In contrast, men with low-risk PC who were older than 65 years at diagnosis had a lower risk of PC death (3%-5%) and more remaining life-years without active PC treatment (62%-77%).The findings of this Swedish cohort study suggest that active surveillance may be a safe strategy for disease management among men with PC who were older than 65 years at diagnosis.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Cancer och onkologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Cancer and Oncology hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Njurmedicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Nephrology hsv//eng
MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine hsv//eng
Aged
Cohort Studies
Humans
Male
Middle Aged
Prostatic Neoplasms
diagnosis
epidemiology
therapy
Risk
Sweden
epidemiology
Watchful Waiting

Biuppslag (personer, institutioner, konferenser, titlar ...)

Bill-Axelson, AnnaUppsala universitet,Urologkirurgi(Swepub:uu)anbil030 (författare)
Bratt, Ola,1963Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology,Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Urol, Gothenburg, Sweden.(Swepub:gu)xbraol (författare)
Montorsi, FrancescoIRCCS Osped San Raffaele, Div Expt Oncol, Urol Res Inst, Unit Urol, Milan, Italy. (författare)
Stattin, PärUppsala universitet,Urologkirurgi(Swepub:uu)parst892 (författare)
Garmo, HansUppsala universitet,Institutionen för kirurgiska vetenskaper,Uppsala Univ Hosp, Reg Canc Ctr, Uppsala, Sweden.(Swepub:uu)hga27600 (författare)
Uppsala universitetUrologkirurgi (creator_code:org_t)

Sammanhörande titlar

Ingår i:JAMA network open: American Medical Association (AMA)5:92574-3805

Internetlänk

Hitta via bibliotek

JAMA network open (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

1 av 1
Föregående post
Nästa post
Till träfflistan

Hitta mer i SwePub

Av författaren/redakt...: Ventimiglia, Eug ...; Bill-Axelson, An ...; Bratt, Ola, 1963; Montorsi, France ...; Stattin, Pär; Garmo, Hans

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Njurmedicin

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin

Artiklar i publikationen: JAMA network ope ...

Av lärosätet: Göteborgs universitet; Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst. Hantera kakor

LIBRIS.kb.se